ArticleIn vivo (Athens, Greece)
Radiodynamic Therapy Using Local Administration of 5-Aminolevulinic Acid for
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aim5-Aminolevulinic acid (5-ALA) is a natural precursor of protoporphyrin IX (PpIX), a radiosensitizer that selectively accumulates in tumor cells. Radiodynamic therapy (RDT) using 5-ALA has demonstrated antitumor effects after systemic administration; however, its efficacy after local administration remains unclear. This study evaluated the therapeutic efficacy of RDT using locally administered 5-ALA in an osteosarcoma xenograft mouse model. MATERIALS AND
methodsThe murine osteosarcoma cell line (LM8) was subcutaneously inoculated into the backs of 5-week-old male BALB/c mice. After tumor establishment (tumor diameter >10 mm), the mice were randomly assigned to three groups (n=5 per group): control (no treatment), irradiation alone (Rx group; single dose of 5 Gy), and 5-ALA RDT group. In the RDT group, 5-ALA (25 mg/kg equivalent; 500 μg/ml, 1 ml) was locally administered to the peritumoral region, followed by a single dose of 5 Gy X-ray irradiation. Tumor volume and body weight were measured over two weeks. The primary outcome was the change in tumor volume.
resultsFourteen days after treatment, tumor growth was significantly suppressed in the 5-ALA RDT group compared to the control and irradiation groups. No significant differences in body weight were observed among the groups, and no abnormal behaviors were detected. Radiodynamic therapy with locally administered 5-ALA demonstrated significant antitumor effects in a murine model of osteosarcoma. Despite the reduced dose compared to systemic administration, local delivery effectively enhanced the radiosensitizing effect.
conclusionThe local administration of 5-ALA represents a promising and less toxic therapeutic strategy for osteosarcoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.